Literature DB >> 30238807

Pharmacogenomics/updated for precision medicine in dermatology.

Le Hanh Dung Do1, Howard Maibach2.   

Abstract

Pharmacogenomics, a key part of precision medicine, has the potential to tailor drug therapy with the high safety margins and optimized response. Before the Human Genome Project in 2003, articles on pharmacogenomics were limited. The last 15 years have seen significant growth in the field, with gene variant discoveries that play essential roles in individuals' drug response. Dermatology has started to take advantage of this information. This overview shows how pharmacogenomic databases have expanded in the treatment of skin diseases and provides a list of current dermatologic drugs with their FDA-approved biomarkers and clinical implementation.

Entities:  

Keywords:  Clinical implementation; names of dermatologic drugs and their pharmacogenomic biomarkers in various combinations; pharmacogenomics

Mesh:

Substances:

Year:  2018        PMID: 30238807     DOI: 10.1080/09546634.2018.1527434

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  1 in total

1.  Genome-Wide Association Study of Ustekinumab Response in Psoriasis.

Authors:  William T Connell; Julie Hong; Wilson Liao
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.